← Back to guidelines
Anesthesiology36 papers

Subacute cutaneous lupus erythematosus

Last edited: 4/15/2026

Overview

Subacute cutaneous lupus erythematosus (SCLE) is a variant of systemic lupus erythematosus characterized by skin manifestations, often without significant internal organ involvement. 1

Diagnosis

  • Clinical Features: Presence of photosensitive rash, often on sun-exposed areas, with characteristic annular or psoriasiform lesions.
  • Laboratory Tests: Positive antinuclear antibodies (ANA), often with specific anti-Ro/SSA antibodies.
  • Skin Biopsy: Histological examination may show interface dermatitis and vacuolar changes.
  • Differential Diagnosis: Exclude other causes of photosensitive rashes and drug eruptions.
  • Drug-Induced SCLE: Consider history of drug exposure, particularly anesthetics like propofol, as triggers. 1
  • Management

  • First-Line Treatments:
  • - Hydroxychloroquine: Initial treatment, typically 200-400 mg/day. - Topical Corticosteroids: For localized skin lesions.
  • Adjunctive Treatments:
  • - Systemic Corticosteroids: For severe cases, dose adjusted based on severity. - Immunosuppressants: Mycophenolate mofetil or azathioprine in refractory cases.
  • Discontinuation of Triggering Agents: Remove identified drug triggers, such as propofol, if applicable. 1
  • Special Populations

  • Pregnancy: Limited data; close monitoring and individualized management required. 1
  • Pediatrics: Rarely reported; management similar to adults but with cautious dosing.
  • Elderly: Consider comorbidities and potential drug interactions when selecting treatments.
  • Comorbidities: Tailor treatment considering other systemic conditions, especially renal involvement. 1
  • Key Recommendations

  • Identify and Remove Triggering Agents: If drug-induced SCLE is suspected, discontinue the implicated drug (e.g., propofol). (Evidence: Expert opinion) 1
  • Initiate Hydroxychloroquine as First-Line Therapy: Use hydroxychloroquine at doses of 200-400 mg/day for managing SCLE symptoms. (Evidence: Expert opinion) 1
  • Monitor for Photosensitivity and Skin Lesions: Regular follow-up to assess response to treatment and adjust based on clinical improvement. (Evidence: Expert opinion) 1
  • References

    1 Schoenfeldt JA, Howard MA, Masood D, Cormican DS. Propofol Induced Subacute Cutaneous Lupus Erythematosus: A Case Report. A&A practice 2023. link

    Original source

    1. [1]
      Propofol Induced Subacute Cutaneous Lupus Erythematosus: A Case Report.Schoenfeldt JA, Howard MA, Masood D, Cormican DS A&A practice (2023)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG